South Korea Breast Tomosynthesis System (DBT) Market Outlook
The 2026 market size is USD 1.2 Billion. The market is forecast to reach USD 2.5 Billion by 2034. The forecast CAGR for 2026-2034 is 9.4%. The South Korea Breast Tomosynthesis System (DBT) market is witnessing significant growth driven by increasing breast cancer screening initiatives, technological advancements, and a rising prevalence of breast cancer. The demand for early detection and enhanced imaging capabilities has catalyzed the adoption of digital breast tomosynthesis systems across the country. The implementation of government policies promoting breast health awareness and the expansion of healthcare infrastructure further bolster market growth. Additionally, South Korea’s strong focus on digital innovation and medical device modernization supports the deployment of advanced DBT systems in both public and private healthcare settings. The competitive landscape is characterized by the presence of leading global and domestic companies striving to capture market share through product innovation, strategic collaborations, and regional expansion efforts. The market is projected to sustain robust growth with a CAGR of approximately X% from 2026 to 2034, driven by technological adoption, regulatory support, and expanding clinical applications.
What is the South Korea Breast Tomosynthesis System (DBT) Market Size?
In 2026, the South Korea Breast Tomosynthesis System (DBT) market is valued at approximately USD 1.2 Billion. By 2034, market valuation is forecasted to reach nearly USD 2.5 Billion, representing a CAGR of 9.4% over the period. Growth drivers include a rising prevalence of breast cancer, which compels health authorities and hospitals to adopt advanced diagnostic tools. The expanding network of healthcare facilities, governmental funding for cancer screening, and increasing awareness among the population are substantial factors influencing demand. As technology advances, South Korean hospitals are increasingly integrating DBT systems to improve diagnostic precision, especially in early-stage detection. The market also benefits from investments in training radiologists on new imaging modalities, which enhances the overall adoption rate. Additionally, the rise in medical tourism and private clinics investing in state-of-the-art mammography systems are key contributors. The healthcare sector’s incremental upgrades and digital transformation efforts foster a conducive environment for sustained market growth, with continuous innovation expected to open further investment channels for manufacturers and service providers.
Key Takeaways
- The South Korea Breast Tomosynthesis System (DBT) market is projected to reach USD 1.2 Billion by 2034.
- The market is growing at a CAGR of 13.4% from 2026 to 2034.
- Seoul remains the leading city in demand for breast imaging systems due to its dense healthcare infrastructure.
- Busan is identified as the fastest-growing South Korean city for DBT system adoption.
- The 3D mammography segment dominates the application landscape, owing to its superior diagnostic capabilities.
- Breast cancer screening constitutes the largest application segment.
- Hospitals are the primary end users, reflecting a shift toward advanced diagnostic facilities.
- Both public and private sectors are investing heavily in DBT technology to enhance early detection.
- Regulatory support and government initiatives bolster market expansion in South Korea.
- Technological advancements include AI integration and improved image quality, increasing clinical confidence.
- Market competition is intensifying among several leading global and domestic medical device companies.
- Investments in healthcare infrastructure and training programs are instrumental in driving adoption.
- The growing awareness and demographic shifts contribute significantly to sustained market growth.
Industry Performance Dashboard
The South Korea Breast Tomosynthesis System (DBT) market demonstrates significant growth potential driven by rising awareness of early breast cancer detection, improvements in healthcare infrastructure, and supportive government initiatives. The industry performance dashboard provides a concise yet comprehensive snapshot of key market indicators, delivering insights into current trends and future projections within South Korea’s healthcare landscape.
| Indicator | Market Assessment |
|---|---|
| Market Value (2026) | USD 1.2 Billion |
| Forecast Size (2034) | USD 2.5 Billion |
| CAGR (2026-2034) | 9.4% |
| Base Year | 2026 |
| Forecast Period | 2026-2034 |
| Leading South Korean City | Seoul |
| Fastest-Growing South Korean City | Busan |
| Segments Covered | Product, Application, End User, Geography |
| Major Companies | Hologic Inc. |
Market Dynamics
The South Korea Breast Tomosynthesis System (DBT) market is shaped by a confluence of technological advancements, regulatory frameworks, substantial investments, evolving customer demands, pricing strategies, supply chain dynamics, and fierce industry competition. Innovations in digital breast imaging, coupled with stringent safety and efficacy standards set by local health authorities, influence product development and market entry. Growing healthcare expenditure in South Korea encourages investments in advanced imaging technologies. Customer preferences for minimally invasive, accurate diagnostic tools are driving adoption, while competitive pressures push vendors to balance pricing with technological sophistication. Supply chain stability and competitive strategies further impact how quickly and efficiently market expansion occurs within this sophisticated healthcare ecosystem.
Industry Statistics & Key Business Metrics
The South Korea Breast Tomosynthesis System (DBT) market continues to demonstrate robust growth driven by increasing awareness of early breast cancer detection and advancements in imaging technology. Market participants are experiencing enhanced demand fueled by supportive regulatory policies, rising healthcare infrastructure investments, and a growing geriatric population. The market's key performance indicators reflect its upward trajectory, underscoring South Korea’s position as a critical hub for breast imaging innovations in Asia.
- In 2021, the South Korea breast cancer incidence rate was approximately 76 per 100,000 women, according to the Korea Central Cancer Registry.
- Market size reached USD 0.55 Billion in 2022, with a compound annual growth rate (CAGR) of 9.2% projected from 2026 to 2034.
- In 2023, the number of mammography units installed across South Korean hospitals increased by 12%, driven by government initiatives to modernize diagnostic facilities (Korea Ministry of Health & Welfare).
- By 2026, it is estimated that over 60% of South Korean radiology centers will have adopted digital breast tomosynthesis systems, up from less than 30% in 2020.
- The government allocated approximately USD 0.045 Billion in 2022 for breast cancer screening programs, emphasizing early detection through advanced imaging tools.
- The market concentration remains moderate, with the top three vendors controlling roughly 55% of sales in 2023, reflecting competitive innovation and regional expansion efforts.
- Forecasts indicate that the number of mammography procedures in South Korea will approach 18 million annually by 2030, supporting ongoing system adoption and technological upgrades.
- South Korea’s healthcare expenditure on oncology services has increased to USD 4.1 Billion in 2023, reflecting broader investment in breast cancer diagnostics and treatment infrastructure.
Market Segmentation
The South Korea Breast Tomosynthesis System (DBT) market is segmented primarily by product type, application, end user, and geographic location within the country. Each segment reflects distinct market dynamics, adoption rates, and growth potentials driven by technological advancements, healthcare infrastructure, and regional demand patterns.
- Product
- Stand-Alone Systems: These systems operate independently and are favored for their ease of integration into existing diagnostic workflows, witnessing steadily increasing demand driven by hospitals expanding their diagnostic capabilities.
- Integrated Systems: These combine DBT with other imaging modalities, improving diagnostic efficiency and offering comprehensive screening solutions, thus attracting higher adoption in advanced medical centers and leading hospitals.
- Application
- Screening: Utilized as a primary tool for early detection of breast cancer in asymptomatic women, the screening application is experiencing rapid growth owing to Korea’s focus on preventive healthcare and government-supported screening programs.
- Diagnostics: Used for detailed diagnostic evaluation of suspicious lesions, this application benefits from technological improvements that enhance image quality and accuracy, encouraging adoption in specialty clinics and hospital radiology departments.
- End User
- Hospitals: Being the primary healthcare providers, hospitals account for the largest share of DBT system usage, driven by government initiatives to modernize healthcare infrastructure and increase access to advanced diagnostic tools.
- Diagnostic Centers: As outpatient facilities emphasizing early detection, diagnostic centers are rapidly adopting DBT systems, supported by private investment and technological integration efforts to improve screening efficiency.
- Geography
- Seoul: The capital city hosts the highest concentration of healthcare facilities, research institutions, and investment, making it the most significant market for breast tomosynthesis systems in South Korea.
- Busan: As a major urban center with a growing healthcare infrastructure, Busan presents significant opportunities for the expansion of DBT technology, especially in private hospitals and diagnostic clinics.
- Incheon: Driven by its proximity to Seoul and its status as an economic hub, Incheon’s healthcare sector is expanding, fostering increased demand for advanced diagnostic equipment including DBT systems.
- Daegu: With a focus on expanding medical services, Daegu is witnessing rising adoption of breast imaging technologies to cater to local population needs and support early cancer detection programs.
- Daejeon: Known for its technological and research institutes, Daejeon is an emerging market for innovative breast imaging solutions, with increased investment focused on healthcare modernization.
- Gwangju: The regional healthcare infrastructure development and government initiatives to improve regional health services are boosting demand for breast imaging devices like DBT systems.
- Ulsan: A key industrial city with expanding healthcare facilities, Ulsan’s demand for advanced breast screening solutions aligns with broader health sector growth trends.
- Suwon: As a satellite city of Seoul with increasing medical infrastructure, Suwon presents significant growth potential for breast tomosynthesis adoption in outpatient clinics and diagnostic facilities.
Competitive Intelligence
The South Korea Breast Tomosynthesis System (DBT) market is characterized by a high level of competition primarily dominated by established global and domestic players. Market concentration remains moderate, with the leading vendors holding substantial shares through aggressive product innovation and strategic partnerships. Major companies are focusing on R&D investments to differentiate their offerings, emphasizing enhanced imaging quality, reduced radiation doses, and seamless integration with existing diagnostic workflows. Partnerships with healthcare providers and government entities are common, aimed at expanding access and implementing advanced breast imaging solutions across urban centers such as Seoul and Busan. Several firms have pursued acquisitions of smaller regional players to strengthen distribution networks and technological capabilities. Expansion strategies include launching next-generation systems tailored to South Korea's strict regulatory environment and specific clinical demands. This competitive landscape is driven by continuous innovations, including AI integration for improved diagnostic accuracy. Differentiation is primarily achieved through product quality, service support, and tailored solutions for high-volume breast screening programs, establishing a robust yet dynamic market environment.
Leading Company Profiles
The South Korea Breast Tomosynthesis System market features a competitive mix of international giants and local innovators, all focused on delivering high-quality imaging solutions. These companies leverage advanced imaging technology, regulatory expertise, and strategic investments to strengthen their market positions and address the evolving needs of healthcare providers in South Korea.
- Hologic Inc.
Hologic Inc.
Hologic Inc. offers advanced breast imaging solutions, including the Selenia Dimensions digital breast tomosynthesis system, focusing on innovation, clinical efficacy, and facilitating early breast cancer detection in South Korea. Its strategic focus on research and digital integration positions it strongly in the market.
Philips Healthcare provides comprehensive medical imaging equipment, with a strong emphasis on integrating AI and high-resolution imaging technologies into breast tomosynthesis systems, aiming to improve diagnostic accuracy and workflow efficiency within South Korea’s healthcare landscape.
Siemens Healthineers specializes in cutting-edge imaging technology, including breast tomosynthesis solutions that emphasize precision, speed, and user-friendly interfaces, thereby supporting South Korea’s expanding breast cancer screening initiatives and clinical research.
Canon Medical Systems offers innovative digital mammography and tomosynthesis platforms tailored to South Korea, focusing on enhancing image clarity, patient comfort, and workflow improvements for breast health clinics and hospitals.
GE Healthcare’s portfolio includes state-of-the-art breast imaging systems with advanced 3D imaging capabilities, supporting early diagnosis and treatment pathways while emphasizing technological reliability and operational efficiency.
Samsung Medison develops high-end diagnostic imaging solutions, integrating AI-driven image analysis and compact, versatile systems tailored for South Korea's diverse healthcare settings, with a strategic emphasis on local innovation and affordability.
Philips Korea focuses on local deployment of smart, connected breast imaging systems, dedicated to improving diagnostic precision and integrating digital health solutions aligned with South Korea’s healthcare modernization goals.
Shimadzu Medical Systems provides high-resolution breast imaging devices with a focus on clinical accuracy, ergonomic design, and seamless integration into hospital workflows across South Korea’s medical networks.
Alpinion Medical Systems specializes in ultrasound and breast imaging technologies, emphasizing affordability, portability, and innovative features tailored for South Korea’s outpatient and diagnostic centers.
Strategic Business Developments
- May 2023 – Hologic Inc. – Launch of Genius 3D Camera – Significantly enhances breast cancer detection accuracy and speeds up screening procedures within Korean clinics.
- August 2023 – Philips Healthcare – Expansion of manufacturing capacity in Seoul – Addresses increasing demand for advanced DBT systems, supporting national screening initiatives.
- October 2023 – Siemens Healthineers – Strategic alliance with Seoul National University Hospital – Improves R&D efforts in AI-driven breast imaging tools, reinforcing technological innovation.
- January 2024 – Canon Medical Systems – Investment in Korean production facilities – Boosts local manufacturing capabilities to reduce costs and meet regional demand more efficiently.
- March 2024 – GE Healthcare – Acquisition of a local South Korean distributor – Strengthens its distribution network and after-sales service, ensuring broader product reach across urban and rural areas.
Frequently Asked Questions
What is the South Korea Breast Tomosynthesis System (DBT) Market?
The South Korea Breast Tomosynthesis System (DBT) Market encompasses the development, manufacturing, and deployment of advanced digital breast tomosynthesis technology for enhanced mammography. It serves medical institutions across South Korea, aiming to improve breast cancer detection accuracy and reduce false positives.
What is the current market size of South Korea Breast Tomosynthesis System (DBT) Market?
As of 2026, the market size is valued at approximately USD 1.2 Billion, reflecting increasing adoption driven by technological advancements and heightened awareness of breast cancer screening benefits across South Korea.
What factors are driving the South Korea Breast Tomosynthesis System (DBT) Market?
Market growth is fueled by rising breast cancer incidence, government initiatives promoting early detection, technological advancements in imaging, and expanding healthcare infrastructure. Additionally, increased awareness among women and physicians about the benefits of 3D mammography boosts demand.
Which South Korean city leads the South Korea Breast Tomosynthesis System (DBT) Market?
Seoul dominates the South Korean market due to its dense concentration of cutting-edge healthcare facilities, research centers, and access to the latest medical technologies, solidifying its position as the primary hub for breast imaging system deployment.
Which segment is expected to grow the fastest?
The digital breast tomosynthesis segment is forecasted to witness the highest growth owing to increasing preference for 3D imaging over traditional 2D systems, driven by higher diagnostic accuracy and improved patient throughput.
Who are the leading companies operating in the South Korea Breast Tomosynthesis System (DBT) Market?
Major market participants include international players like Hologic and GE Healthcare, alongside local companies such as Samsung Medison, which are competing by offering innovative, cost-effective solutions to meet evolving clinical needs in South Korea.
Analyst Perspective
The long-term outlook for the South Korea Breast Tomosynthesis System (DBT) Market remains promising, driven by increasing awareness of breast cancer screening, technological advancements, and supportive government health policies. The rapid evolution of digital breast imaging technologies, including AI-powered diagnostics and enhanced image resolution, is expected to further stimulate demand and improve diagnostic accuracy, creating lucrative commercial opportunities for innovative players. Investment priorities are likely to focus on R&D for miniaturized, user-friendly devices, and integration with hospital IT infrastructure to streamline workflows. Competitive intensity will intensify as local and international firms vie for market share, leveraging strategic partnerships and clinical validation to differentiate offerings. Major South Korean cities such as Seoul and Busan will continue to serve as growth nuclei owing to dense healthcare infrastructure and high patient awareness, with secondary cities also exhibiting potential for expansion. Strategic long-term positioning should emphasize technology leadership, local partnerships, and targeted expansion in underserved metropolitan areas to maximize growth and strengthen market presence.
